?? ?Product Overview?
?Baloxavir? (CAS: 1985605-59-1) is a groundbreaking third-generation antiviral agent renowned for its efficacy against influenza A and B strains, including oseltamivir-resistant variants and avian flu subtypes (e.g., H7N9, H5N1)?3. As a single-dose oral medication, it inhibits viral replication by targeting the cap-dependent endonuclease complex, offering rapid symptom relief and reduced transmission risk?23. Widely utilized in ?pharmaceuticals?, ?clinical therapy?, and ?public health initiatives?, it is a critical tool for global influenza management.

? ?Key Advantages?
?? ?Single-Dose Efficacy?: Reduces treatment duration with 48-hour symptom improvement in 90% of cases?3.
?? ?High Purity?: ≥99% HPLC/GC-certified quality, ensuring optimal therapeutic outcomes?4.
?? ?Stability?: Stable under ambient or storage conditions for long-term use?14.
?? ?Structural Verification?: Supported by NMR, MS, and chromatographic data for batch consistency?1.

?? ?Applications?
? ?Pharmaceutical Manufacturing?: Active ingredient in antiviral formulations.
? ?Clinical Use?: Approved for adults and pediatric influenza treatment.
? ?Public Health?: Prophylaxis during avian flu outbreaks and pandemics?3.

?? ?Quality Certifications?
? Complies with ?USP/EP standards? for impurities and stability.
? Batch-specific COA, including purity (≥99%), residual solvents, and heavy metals?14.
? Rigorous testing via HPLC (>95% purity default), NMR, and mass spectrometry?1.

?? ?Market Trends?
The global antiviral drug market is projected to grow at ?6.8% CAGR (2025-2030)?, driven by rising influenza incidence and drug resistance?3. Baloxavir, endorsed by FDA and PMDA, dominates 22% of the anti-flu segment, with increasing adoption in Asia-Pacific and North America?3.